US4721713A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for inhibiting blood platelet aggregation and promoting vasodilation
Assignee: Asahi Kasei Corp
•
Filing: 1987-06-05
•
Granted: 1988-01-26
•
Expires: 2007-06-05
Abstract
Abstract A method for inhibiting blood platelet aggregation in humans, and promoting vasodilation in humans, by administering to a human in need of the same an effective amount of 2-hydroxy-3-isopropyl-5,6-dimethylpyrazine or a hydrate or a pharmaceutically acceptable non-toxic salt thereof. Administration can be orally in an amount of about 0.02-12 mg/kg body weight per day, or parenterally in an amount of about 0.01-6 mg/kg of body weight per day.
Inventors
- 👤 Eiichi Hayashi
- 👤 Noriyasu Takayanagi
- 👤 Katsumi Nishimura
- 👤 Masao Yaso
- 👤 Yukio Suzuki
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:23
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61P; A61P7/00; A61P7/02
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
47 words
A method of inhibiting blood platelet aggregation in humans, comprising administering to a human in the need of the same an effective amount of 2-hydroxy-3-isopropyl-5,6-dimethylpyrazine or a hydrate or a pharmaceutically acceptable non-toxic salt thereof, said amount being effective to inhibit blood platelet aggregation in a human.
Claim 2
Independent Claim
47 words
A method of inhibiting blood platelet aggregation in humans, comprising administering to a human in the need of the same an effective amount of 2-hydroxy-3-isopropyl-5,6-dimethylpyrazine or a hydrate or a pharmaceutically acceptable non-toxic salt thereof, said amount being effective to inhibit blood platelet aggregation in a human.
Claim 3
Dependent Claim
25 words
A method as claimed in claim 1, in which said administration is effected orally and said amount is about 0.02-12 mg/kg body weight per day.
Claim 4
Dependent Claim
26 words
A method as claimed in claim 1, in which said administration is effected parenterally and said amount is about 0.01-6 mg/kg of body weight per day.
Claim 5
Independent Claim
42 words
A method for promoting vasodilation in humans, comprising administering to a human in need of the same an effective amount of 2-hydroxy-3-isopropyl-5,6-dimethylpyrazine or a hydrate or a pharmaceutically acceptable non-toxic salt thereof, said amount being effective to promote vasodilation in a human.
Claim 6
Independent Claim
42 words
A method for promoting vasodilation in humans, comprising administering to a human in need of the same an effective amount of 2-hydroxy-3-isopropyl-5,6-dimethylpyrazine or a hydrate or a pharmaceutically acceptable non-toxic salt thereof, said amount being effective to promote vasodilation in a human.
Claim 7
Dependent Claim
25 words
A method as claimed in claim 4, in which said administration is effected orally and said amount is about 0.02-12 mg/kg body weight per day.
Claim 8
Dependent Claim
26 words
A method as claimed in claim 4, in which said administration is effected parenterally and said amount is about 0.01-6 mg/kg of body weight per day.
References Cited (Backward Citations)
US3720768A
Cited
US4599413A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-01-25 | 1991-07-27 | 1992-01-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-01-25 | 1995-07-27 | 1996-01-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-01-25 | 1999-07-27 | 2000-01-26 | $7700.00 | Window Closed / Lapsed |